Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ception Therapeutics
With
Cephalon
Subjects will enter this open-label extension study after completing the placebo-controlled, double-blind study Res-5-0002 (NCT00538434). The end of study visit for Res-05-0002 will serve as the screening visit for this trial.
All subjects will receive reslizumab and be followed by their principal investigators in an unblinded fashion. Visits and administration of reslizumab will be monthly.
Age
5–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent
Received at least two doses of study drug in Study Res-05-0002 (NCT00538434)
Did not withdraw from Study Res-05-0002 due to drug related adverse event
Completed End of Treatment Visit for Study Res-05-0002
You may not be if
Pregnant or nursing females
Concurrent Immunodeficiency
Current use of immunosuppressive drugs
Did not tolerate study drug in Study Res-05-0002
Clareo Health | Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
